UOC
SLRN

UBS O'Connor’s ACELYRIN SLRN Stock Holding History

UBS O'Connor’s Portfolio SLRN Stock Details SLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-211,938
Closed -$665K – 443
2024
Q4 		$665K Buy
211,938
+48,214
+29% +$233K 0.02% 261
2024
Q3 		$807K Buy
163,724
+82,312
+101% +$425K 0.02% 298
2024
Q2 		$359K Buy
81,412
+10,000
+14% +$46.9K 0.01% 383
2024
Q1 		$482K Buy
71,412
+11,412
+19% +$86.7K 0.01% 337
2023
Q4 		$448K Buy
+60,000
New +$512K 0.01% 364

Other funds holding SLRN

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACMC
AyurMaya Capital Management Company Portsmouth, New Hampshire $148M AUM 24.4% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return

UBS O'Connor's SLRN Position: Q1 2025 in Review

UBS O'Connor sold out of ACELYRIN (SLRN) in Q1 2025, closing a stake of 211,938 shares — an estimated $665K sold.

UBS O'Connor first reported a position in SLRN in Q4 2023 and held it in 5 quarters. The position peaked at $807K in Q3 2024. 105 funds tracked by Wall St. Rank hold SLRN as of Q1 2025.

  • UBS O'Connor reported no remaining ACELYRIN position as of Q1 2025 after selling out during the quarter.
  • UBS O'Connor sold 211,938 ACELYRIN shares in Q1 2025, an estimated $665K.
  • UBS O'Connor first reported a position in ACELYRIN in Q4 2023 and held it in 5 quarters.
  • UBS O'Connor's ACELYRIN position peaked at $807K in Q3 2024.
  • 105 funds tracked by Wall St. Rank held ACELYRIN as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.